SORT

Yutong Bus Picks Up Prestigious Award at Busworld Europe 2023

Retrieved on: 
Monday, October 9, 2023

BRUSSELS, Oct. 9, 2023 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a leading global manufacturer of electric buses, makes a splash at the recent Busworld Europe 2023 event in Brussels, showcasing four state-of-the-art electric bus models along with its latest YEA technology.

Key Points: 
  • BRUSSELS, Oct. 9, 2023 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a leading global manufacturer of electric buses, makes a splash at the recent Busworld Europe 2023 event in Brussels, showcasing four state-of-the-art electric bus models along with its latest YEA technology.
  • Highlighting its commitment to ecological sustainability, Yutong is also honored with the prestigious Busworld Design and Ecology Award.
  • Yutong's display comprised four models, namely, the world-class U11DD double-decker sightseeing bus, the 18-meter large-capacity U18, the E7S mini electric bus, and the luxurious 15-meter T15E.
  • Notably, Yutong's T15E model is the only pure electric highway bus to receive an award at the exhibition, affirming the company's leadership in electric mobility innovation.

Yutong Bus Picks Up Prestigious Award at Busworld Europe 2023

Retrieved on: 
Monday, October 9, 2023

BRUSSELS, Oct. 9, 2023 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a leading global manufacturer of electric buses, makes a splash at the recent Busworld Europe 2023 event in Brussels, showcasing four state-of-the-art electric bus models along with its latest YEA technology.

Key Points: 
  • BRUSSELS, Oct. 9, 2023 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a leading global manufacturer of electric buses, makes a splash at the recent Busworld Europe 2023 event in Brussels, showcasing four state-of-the-art electric bus models along with its latest YEA technology.
  • Highlighting its commitment to ecological sustainability, Yutong is also honored with the prestigious Busworld Design and Ecology Award.
  • Yutong's display comprised four models, namely, the world-class U11DD double-decker sightseeing bus, the 18-meter large-capacity U18, the E7S mini electric bus, and the luxurious 15-meter T15E.
  • Notably, Yutong's T15E model is the only pure electric highway bus to receive an award at the exhibition, affirming the company's leadership in electric mobility innovation.

ReCode Therapeutics Announces Closing of Extension to Series B Financing

Retrieved on: 
Tuesday, September 19, 2023

ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.
  • The company recently concluded a final extension to its Series B financing, raising an additional $50 million, for a total of $260 million in funding.
  • At BLV, we focus on funding next-generation therapeutics platforms and developing first- and best-in-class programs.
  • ReCode, with its cutting-edge genetic medicine platform, is well aligned with our mission,” said Dr. Harasaki.

ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

Retrieved on: 
Monday, April 17, 2023

ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
  • Dr. Matthews will oversee clinical development planning and strategy.
  • “We are delighted to welcome Dr. Matthews to build and lead our clinical team,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
  • He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director.

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

Retrieved on: 
Wednesday, March 15, 2023

Patients with PCD have a high burden of morbidity with chronic respiratory infections and bronchiectasis, and often develop respiratory failure.

Key Points: 
  • Patients with PCD have a high burden of morbidity with chronic respiratory infections and bronchiectasis, and often develop respiratory failure.
  • RCT1100 is designed to be a disease-modifying mRNA-based therapeutic for PCD caused by pathogenic mutations in DNAI1, a gene that encodes a protein essential for ciliary movement.
  • The intent is for the mRNA delivery to lead to DNAI1 protein production in target cells and thereby rescue ciliary function.
  • The study is being conducted in New Zealand and ReCode anticipates enrolling approximately 32 healthy adults who will receive a single dose of either placebo or RCT1100.

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

Retrieved on: 
Wednesday, March 8, 2023

The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.

Key Points: 
  • The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.
  • Additionally, the consensus report endorses Castle’s DecisionDx®-Melanoma GEP risk stratification test as offering more utility than other existing CM GEP assays or nomograms, supported by extensive, evidence-driven data in current literature.
  • The panel reviewed 32 studies published between 2019 through 2022 assessing the use of GEP testing in CM prognosis.
  • Each of the recommendations was given a strength “A,” “B,” or “C” according to Strength of Recommendation Taxonomy (SORT) criteria.

AI-Powered Kindred INDUCT Automates Induction of One Million Items with 95% Accuracy

Retrieved on: 
Monday, January 30, 2023

Kindred, part of Ocado Group, has released the results of an 18-month beta test of its INDUCT AI-powered robotic induction system.

Key Points: 
  • Kindred, part of Ocado Group, has released the results of an 18-month beta test of its INDUCT AI-powered robotic induction system.
  • INDUCT automated the induction of more than one million items at 95% accuracy in a grueling, fast-paced global logistics center where the beta trial was held.
  • View the full release here: https://www.businesswire.com/news/home/20230130005022/en/
    A beta test was designed to put the Kindred INDUCT system through its paces in one of the most grueling and fast-paced logistics environments.
  • During the beta, INDUCT automated the induction of more than one million items at 95% accuracy.

ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy

Retrieved on: 
Tuesday, January 10, 2023

“We are excited to expand our relationship with the CF Foundation with this investment in our CFTR mRNA program for cystic fibrosis,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.

Key Points: 
  • “We are excited to expand our relationship with the CF Foundation with this investment in our CFTR mRNA program for cystic fibrosis,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.
  • The investment includes a commitment by the CF Foundation to invest another $5 million upon completion of development milestones.
  • ReCode’s CFTR mRNA therapy aims to compensate for mutated CFTR, the fundamental genetic defect in CF.
  • Preclinical data from ReCode presented at the North American Cystic Fibrosis Conference in 2022 demonstrated that CFTR mRNA encapsulated in SORT LNPs can be nebulized and delivered as an aerosol.

ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform

Retrieved on: 
Monday, January 9, 2023

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG.

Key Points: 
  • ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG.
  • This strategic collaboration is focused on the discovery of precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.
  • The collaboration could extend the reach of gene editing for liver and lung disease targets.
  • Proceeds from the financing are being used to advance the development of ReCode’s platform and pipeline to selectively deliver genetic medicines to targeted organ and cell types in a predictable and programmable fashion.

AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform

Retrieved on: 
Monday, January 9, 2023

Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.

Key Points: 
  • Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.
  • This represents another step forward for AskBio in developing its gene editing and other nonviral delivery technologies and expertise.
  • "Through this collaboration, we have an opportunity to advance AskBio's gene editing and nonviral delivery efforts, which support and align with our commitment to serve as an industry-leading engine of gene therapy innovation."
  • This collaboration could extend the reach of gene editing for liver and lung disease targets.